Download MendeleyIdentification of small molecule inhibitors of anthrax lethal factor.
Panchal, R.G., Hermone, A.R., Nguyen, T.L., Wong, T.Y., Schwarzenbacher, R., Schmidt, J., Lane, D., McGrath, C., Turk, B.E., Burnett, J., Aman, M.J., Little, S., Sausville, E.A., Zaharevitz, D.W., Cantley, L.C., Liddington, R.C., Gussio, R., Bavari, S.(2004) Nat Struct Mol Biol 11: 67-72
- PubMed: 14718925
- DOI: https://doi.org/10.1038/nsmb711
- Primary Citation of Related Structures:
1PWP - PubMed Abstract:
The virulent spore-forming bacterium Bacillus anthracis secretes anthrax toxin composed of protective antigen (PA), lethal factor (LF) and edema factor (EF). LF is a Zn-dependent metalloprotease that inactivates key signaling molecules, such as mitogen-activated protein kinase kinases (MAPKK), to ultimately cause cell death. We report here the identification of small molecule (nonpeptidic) inhibitors of LF. Using a two-stage screening assay, we determined the LF inhibitory properties of 19 compounds. Here, we describe six inhibitors on the basis of a pharmacophoric relationship determined using X-ray crystallographic data, molecular docking studies and three-dimensional (3D) database mining from the US National Cancer Institute (NCI) chemical repository. Three of these compounds have K(i) values in the 0.5-5 microM range and show competitive inhibition. These molecular scaffolds may be used to develop therapeutically viable inhibitors of LF.
Organizational Affiliation:
Developmental Therapeutics Program, NCI Frederick, Frederick, Maryland 21702-1201, USA. panchal@dtpax2.ncifcrf.gov
